泰索帝联合希罗达治疗蒽环类化疗失败复发转移性乳腺癌的临床研究  

The clinical study of docetaxel-capecitabine combination in treatment of metastatic breast cancer patients failed prior treatment with anthracyclin

作　　者：张少华[1] 江泽飞[1] 宋三泰[1] 申戈[1] 王涛[1] 曾敏[1] 郭中宁[1] 

机构地区：[1]军事医学科学院307医院乳癌内科,北京100039

出　　处：《癌症进展》2004年第3期217-220,共4页Oncology Progress

摘　　要：目的 研究泰索帝联合希罗达治疗蒽环类药物治疗失败复发转移性乳腺癌的疗效和安全性。方法 18例蒽环类药物治疗失败的复发转移性乳腺癌患者均接受泰索帝联合希罗达方案治疗,随机分为A组:泰索帝75mg/m2静滴,第1天;希罗达950mg/m2口服,每日2次,第1-14天,每3周为1周期;B组:泰索帝37.5mg/m2静滴第1、8天;希罗达950mg/m2口服,每日2次,第1-14天,每3周为1周期。每周期评价疗效同时记录不良事件。结果 18例患者均可评价疗效,完全缓解(CR)无,部分缓解(PR)13例,有效率(CR+PR)72％(13/18)。A组有效率88.9％(8/9),B组有效率55.6％(5/9)。两组共56周期可评价:毒性反应,无严重不良事件导致死亡的患者,中性粒细胞减少是主要不良反应,Ⅲ-Ⅳ度占58.9％,A组Ⅳ度中性粒细胞减少30.9％,B组3.7％(P=0.012)。结论泰索帝联合希罗达是治疗蒽环类药物治疗失败复发转移性乳腺癌的有效方案,其不良反应能够耐受。Objective To evaluate the efficacy and toxicity of docetaxel-capecitabine combination in patients with metastatic breast cancer who failed prior treatment with anthracyclin. Methods Eighteen patients were randomized into group A or group B. Group A received docetaxel 75mg/m2 iv d1, capecitabine 950mg/m2 po bid, d1- 14, once every 3 weeks. Group B received docetaxel 37.5mg/m2 iv d1 and d8, capecitabine 950mg/m2 po bid, d1 - 14, once every 3 weeks. Results Eighteen patients were evaluated for response. The overall clinical response rate of all groups was 72% (13/18). There were no complete response (CR) and progress disease (PD), 13 partial response (PR) and 5 stable disease (SD). The response rate of group A and B were 88.9% (8/9) and 55.6% (5/9) respectively. Fifty-six cycles were evaluated for the toxicity. There was no serious adverse event lead to death. Major toxicity was neurotoxicity. The incidence of grade Ⅲ and Ⅳ in all groups were 58.9% . The incidence of grade Ⅳ in group A and B were 30.9% and 3.7% respectively (P = 0.012). Conclusion The combination of docetaxel and capecitabine is an effective regimen for the patients who failed prior treatment with anthracyclin. Overall toxicity was acceptable.

关 键 词：乳腺癌 化学治疗 泰索帝 希罗达 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]